From medical oncology standpoint, it may be worthwhile to send HER2(+) cILC cases with uncertain prognosis potential to BluePrint, MammaPrint or Oncotype Dx test to obtain a more comprehensive molecular genetic picture of the tumor, that may help oncologists make treatment decision for management of this rare subset of HER2 (+) low grade breast cancer. Here, ERBB2 is linked to breast cancer.